Martin D - Search Results

1

Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.

Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R. Seiter K, et al. Among authors: martin d. Cancer. 1993 Mar 1;71(5):1875-81. doi: 10.1002/1097-0142(19930301)71:5<1875::aid-cncr2820710526>3.0.co;2-9. Cancer. 1993. PMID: 8448752

2

Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.

Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W. Kemeny N, et al. Among authors: martin d. J Clin Oncol. 1992 May;10(5):747-52. doi: 10.1200/JCO.1992.10.5.747. J Clin Oncol. 1992. PMID: 1569447

3

A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA).

Kemeny N, Seiter K, Martin D, Urmacher C, Niedzwiecki D, Kurtz RC, Costa P, Murray M. Kemeny N, et al. Among authors: martin d. Ann Intern Med. 1991 Dec 15;115(12):946-51. doi: 10.7326/0003-4819-115-12-946. Ann Intern Med. 1991. PMID: 1824554 Clinical Trial.

4

Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination.

Stolfi RL, Colofiore JR, Nord LD, Koutcher JA, Martin DS. Stolfi RL, et al. Among authors: martin ds. Cancer Res. 1992 Aug 1;52(15):4074-81. Cancer Res. 1992. PMID: 1379119

5

A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.

Kelsen D, Martin DS, Colofiore J, Sawyer R, Coit D. Kelsen D, et al. Among authors: martin ds. Cancer. 1992 Oct 1;70(7):1988-92. doi: 10.1002/1097-0142(19921001)70:7<1988::aid-cncr2820700730>3.0.co;2-k. Cancer. 1992. PMID: 1381991 Clinical Trial.

6

Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials.

Martin DS, Kemeny NE. Martin DS, et al. Semin Oncol. 1992 Apr;19(2 Suppl 3):228-33. Semin Oncol. 1992. PMID: 1557654 Review.

7

Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.

Martin DS, Kemeny NE. Martin DS, et al. Semin Oncol. 1992 Apr;19(2 Suppl 3):49-55. Semin Oncol. 1992. PMID: 1557657 Review.

8

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.

O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF. O'Dwyer PJ, et al. Among authors: martin ds. J Natl Cancer Inst. 1991 Sep 4;83(17):1235-40. doi: 10.1093/jnci/83.17.1235. J Natl Cancer Inst. 1991. PMID: 1714507 Clinical Trial.

9

Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.

Kemeny NE, Schneider A, Martin DS. Kemeny NE, et al. Among authors: martin ds. Cancer Invest. 1990;8(2):263-4. doi: 10.3109/07357909009017578. Cancer Invest. 1990. PMID: 2400946 No abstract available.

10

Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.

Kemeny N, Schneider A, Martin DS, Colofiore J, Sawyer RC, Derby S, Salvia B. Kemeny N, et al. Among authors: martin ds. Cancer Res. 1989 Aug 15;49(16):4636-9. Cancer Res. 1989. PMID: 2472883

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,251 results

Search Page

Filters